Eyebright Medical Technology Beijing (688050) Report Interpretation

Overview

This earnings review examines Eyebright Medical Technology Beijing's 2Q26 and 1H26 results. UBS highlights consolidation-led revenue growth, led in part by Delta Medical, but concludes that weaker margins and higher expenses are holding back earnings.

Core views

Eyebright reported 2Q26 revenue of Rmb535m, up 24.5% year on year but 3.3% below UBS's Rmb553m estimate. Net profit attributable to shareholders was Rmb93m and recurring net profit was Rmb88m, down 22.7% and 25.3% year on year, respectively, and 6.5% below UBS estimates. For 1H26, revenue rose 18.6% year on year to Rmb933m, while net profit attributable to shareholders and recurring net profit declined 14.4% and 13.5% to Rmb183m and Rmb177m. Operating cash flow also fell 22.0% year on year. Segment performance was uneven. First-half intraocular-lens revenue declined 11.3% year on year to Rmb306m, which UBS attributes to business contraction at some medical institutions and adjustments to the medical-insurance payment structure. Contact-lens revenue increased 18.7% to Rmb281m and retained solid growth momentum, while orthokeratology-lens revenue grew 4.2% to Rmb124m. Following the consolidation of Delta Medical, sports medicine contributed Rmb94m in revenue and became a new growth driver. The report identifies profitability as the principal reason earnings lagged revenue. In 2Q26, gross profit margin fell 4.2 percentage points year on year to 61.6%, the selling-expense ratio increased 8.7 percentage points to 23.8%, and net profit margin narrowed 10.7 percentage points to 17.5%. UBS therefore sees the revenue contribution from consolidation as insufficient to offset the combined drag from lower gross margin and higher operating expenses. UBS values the company using DCF, applying a 9.3% WACC and 2.5% terminal growth rate, to derive a Rmb40.00 price target. With the share price at Rmb41.80 on 25 August 2026, UBS maintains a Neutral 12-month rating. Its forecast price appreciation is -4.3%; adding a 1.0% forecast dividend yield produces a forecast stock return of -3.3%, versus a 6.8% market-return assumption and a forecast excess return of -10.1%.

Analysis framework

UBS reviews the quarterly and first-half revenue and earnings outcomes against its estimates, then breaks results down by ophthalmic-product segments and Delta Medical's consolidation contribution. It links the gap between revenue growth and profit decline to gross-margin compression and a higher selling-expense ratio, before applying a DCF valuation framework to set the price target.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  UBS discounts expected future cash flows using a 9.3% WACC and 2.5% terminal growth rate to derive its Rmb40.00 price target.

• Industry AnalysisVolume-price decomposition

  Segment-level revenue and margin analysis

  The report separates revenue performance across IOL, contact lenses, orthokeratology lenses and sports medicine, then explains earnings pressure through gross-margin and expense-ratio changes.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Eyebright Medical Technology Beijing (688050.SH)

  Primary covered company; revenue growth is supported by Delta Medical consolidation, while profitability is pressured by margin compression and higher expenses.

  Strengths

  Contact lenses maintained solid growth momentum, and Delta Medical contributed Rmb94m of 1H26 sports-medicine revenue.

  Weaknesses

  IOL revenue fell 11.3% YoY in 1H26; 2Q26 gross margin declined and the selling-expense ratio increased.

  Comparison

  2Q26 revenue was 3.3% below UBS estimates and profit was 6.5% below UBS estimates.

  Risks

  Pricing pressure, competition, weaker recovery in ophthalmic-device and optical-product sales, substitutes for ortho-k lenses, and medical accidents could reduce demand.

Key data

• 2Q26 revenueRmb535m+24.5% YoY and 3.3% below UBS's Rmb553m estimate
• 2Q26 net profit attributable to shareholdersRmb93m-22.7% YoY and 6.5% below UBS estimates
• 2Q26 recurring net profitRmb88m-25.3% YoY and 6.5% below UBS estimates
• 1H26 revenueRmb933m+18.6% YoY
• Delta Medical sports-medicine revenueRmb94m1H26 contribution after consolidation
• 2Q26 gross profit margin61.6%-4.2ppt YoY
• 2Q26 selling-expense ratio23.8%+8.7ppt YoY
• 2Q26 net profit margin17.5%-10.7ppt YoY

Impact & implications

UBS views Delta Medical consolidation and contact-lens growth as supporting top-line expansion, but considers recovery in IOL demand, improved expense efficiency and stabilization of margins necessary for earnings to better match revenue growth. The valuation supports a Neutral rating rather than a positive return outlook at the reported share price.

Risks

• A weaker-than-expected recovery in sales of ophthalmic-surgery medical devices and optical products after the COVID pandemic could weigh on results.
• Reforms targeting high-value medical consumables, including GPOs, could pressure pricing.
• Intensifying market competition could reduce profitability.
• Disruption in the myopia-correction market or substitutes for orthokeratology lenses could weaken demand.
• Medical accidents could reduce demand.
• Industry risks include continued GPO price reductions, persistent COVID effects, and product-development or qualification-approval risks.

What to watch

• Recovery in the intraocular-lens segment.
• The input-output efficiency of the contact-lens segment.
• Progress in consolidating the sports-medicine business.
• Whether expense ratios can gradually decline.
• Signs of PRL revenue ramp-up, the price-volume outcome for EDoF and high-end IOLs in national VBP, contact-lens gross-margin expansion, and Delta Medical's profit, overseas-expansion and synergy progress.